from proactiveinvestors Australia by John Harrington Cash-rich stem cell therapy development company ReNeuron (LON:RENE) is starting to press harder on the accelerator with some of its programmes. The firm’s interim results, covering the six months to end-September, were largely about recapping the ...
Read More »